Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483554 | 1.00 | SIGMAR1 (0.59) | SIGMAR1BCHETACR1TSHRALDH1A1 | |
| SCHEMBL2715155 | 0.89 | BCHE (0.56) | SIGMAR1BCHEALDH1A1CA1CA2 | |
| SCHEMBL9625673 | 0.86 | SIGMAR1 (0.59) | SIGMAR1BCHETACR1TSHRCA1 | |
| SCHEMBL21444695 | 0.81 | TAAR1 (0.57) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL25666197 | 0.81 | TAAR1 (0.57) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL28751212 | 0.81 | CTSS (0.47) | SIGMAR1TACR1TSHRCYP2D6CA1 | |
| SCHEMBL13995917 | 0.80 | TACR1 (0.46) | SIGMAR1BCHETACR1TSHRCA1 | |
| SCHEMBL3559030 | 0.80 | TSHR (0.50) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL27526858 | 0.80 | MAOA (0.58) | SIGMAR1TACR1TSHRCA1CA2 | |
| SCHEMBL1006250 | 0.79 | SIGMAR1 (0.51) | SIGMAR1BCHEALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671068-B2 | N-(alkoxyalkyl) carbamoyl-substituted 6-phenyl-benzonaphthyridine derivatives and their use as PDE ¾ inhibitors | NYCOMED GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-20070208051-A1 | Novel N-(Alkoxyalkyl) Carbamoyl-Substituted 6-Phenyl-Benzonaphthyridine Derivatives and their Use as Pde 3/4 Inhibitors | ALTANA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1732925-A1 | NOVEL N-(ALKOXYALKYL)CARBAMOYL- SUBSTITUTED 6-PHENYL-BENZONAPHTHYRIDINE DERIVATIVES AND THEIR USE AS PDE3/4 INHIBITORS | Altana Pharma AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090345-A1 | NOVEL N- (ALKOXYALKYL) CARBAMOYL - SUBSTITUTED 6-PHENYL-BENZONAPHTHYRIDINE DERIVATIVES AND THEIR USE AS PDE3/4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208051-A1 | Novel N-(Alkoxyalkyl) Carbamoyl-Substituted 6-Phenyl-Benzonaphthyridine Derivatives and their Use as Pde 3/4 Inhibitors | PDE3A, PDE4A, PDE5A | SIGMAR1 1634/4885BCHE 76/4885TACR1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.